HWPC(SH:688799) Zheng Quan Zhi Xing·2025-09-03 16:28Core Viewpoint - The announcement details a change in shareholding by major shareholders of Hunan Warner Pharmaceutical Co., Ltd., specifically a reduction in shareholding by over 5% by shareholder Xu Xiaoqiang and his concerted action partner Xu Yan, which has implications for the company's governance structure and investor perception [1][6]. Group 1: Shareholding Changes - Xu Xiaoqiang reduced his shareholding from 15.57% to 15.00%, a decrease of 0.57% [1][6]. - The reduction involved the sale of 757,120 shares, representing 0.58% of the total share capital [1][6]. - The shareholding change was executed through centralized bidding transactions from September 1 to September 3, 2025 [1][6]. Group 2: Compliance and Governance - The shareholding change does not trigger mandatory tender offer obligations and does not violate any prior commitments or plans [1][6]. - The reduction in shareholding does not affect the company's status regarding its controlling shareholders or actual controllers, ensuring stability in governance [6][7]. - The company will continue to monitor compliance with relevant regulations and ensure timely disclosure of information to investors [7].